• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EU’s CTIS Set for Takeoff at End of January 2022

EU’s CTIS Set for Takeoff at End of January 2022

August 9, 2021

All systems are go for the EU’s Clinical Trials Information System (CTIS), with the European Commission disclosing that the IT technology platform will be launched as planned on Jan. 31.

The launch of the CTIS will bring the long-awaited Clinical Trials Regulation (CTR) into effect. Multiple technical problems had repeatedly pushed back the launch of the CTIS, and consequently the CTR, but it now appears that those have been ironed out.

Under the EU’s revamped clinical trial regulations, which will replace the current Clinical Trials Directive, the CTIS must be used for new clinical trials starting Jan. 31, 2023, meaning there will be a year’s time in which trial applicants still have the option of submitting their trial applications via the current system.

As of Jan. 31, 2025, all ongoing trials approved under the EU’s current trial requirements will be required to transition to the CTR, the commission said. To help prepare applicants prior to launch, the European Medicines Agency has posted training resources online that detail how to use the new system.

The CTIS will serve as the sole gateway for trial application submission, authorization and monitoring in the EU, as well as Iceland, Liechtenstein and Norway, which are members of the European Economic Area, the commission said. Currently, sponsors must submit their trial applications separately to national competent authorities and ethics committees in each country in order to be approved to conduct a trial.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing